作者: Pullman, Daryl ; Barreto, Philipe de Souto ; Newman, John C ; Harrington, Lea ; Côté, Hélène ; Muscedere, John ; Chevalier, Stéphanie ; Hajj-Boutros, Guy ; Carrington-Lawrence, Stacy ; Fowler, Robert ; Morais, José A ; Abumrad, Naji ; Kim, Perry ; Bowdish, Dawn ; Van Raamsdonk, Jeremy ; Aubertin-Leheudre, Mylene ; Sierra, Felipe ; Howlett, Susan ; Kuchel, George ; Gouspillou, Gilles ; Rylett, Rebecca Jane ; Mallette, Frédérick A ; Bergman, Howard ; Duque, Gustavo ; Dawe, David E ; Watt, Jennifer ; Lautrup, Sofie ; Kirkland, James ; Faust, Andréa ; Farrelly, Colin ; Burford, Jessica ; Imani, Mahdi

Abstract:

The inaugural Canadian Conferences on Translational Geroscience were held as 2 complementary sessions in October and November 2023. The conferences explored the profound interplay between the biology of aging, social determinants of health, the potential societal impact of geroscience, and the maintenance of health in aging individuals. Although topics such as cellular senescence, molecular and genetic determinants of aging, and prevention of chronic disease were addressed, the conferences went on to emphasize practical applications for enhancing older people’s quality of life. This article summarizes the proceeding and underscores the synergy between clinical and fundamental studies. Future directions highlight national and global collaborations and the crucial integration of early-career investigators. This work charts a course for a national framework for continued innovation and advancement in translational geroscience in Canada.

2023-12-01·Cold Spring Harbor perspectives in medicine

Funding Life-Extension Research

Article

作者: Khan, Mehmood

While the worldwide trend in life expectancy continues to increase slightly overall, the trend for the last few decades in developed countries is that more people are spending more years in poor health with multiple chronic comorbidities. These chronic conditions in aging populations consume high proportions of national healthcare budgets. The relatively young field of longevity research, after accumulating insights into the mechanisms of aging and producing dramatic laboratory demonstrations of life extension in some organisms, is entering the translational phase. This phase, through clinical trials, will confirm or refute the "geroscience hypothesis" that drugs can change the trajectory of the processes of aging within cells, and ultimately in living humans. At the same time, traditional funding patterns do not favor such visionary "moonshot" research, which, despite the potential for ultimately providing benefits for everyone, offers little prospect for rapid return on investment and high probabilities for early phase failure. New radical funding strategies incentivizing innovation will have to be called into play.

2022-07-01·Saudi journal of biological sciences

Clinical characteristics, risk factors, and rate of severity of a nationwide COVID-19 Saudi cohort

Article

作者: Al-Numair, Nouf S ; Halwani, Rabih ; Alyounes, Banan ; Al-Muhsen, Saleh ; Al-Saud, Haya

Objective:

To evaluate COVID19 patients' clinical characteristics, risk factors, and COVID-19 severity at baseline and over one month following hospitalization.

Design setting and participants:

This prospective cohort study of 598 Saudi COVID19 patients recruited from 4 major medical institutions nationwide between June 01, 2020, and February 28, 2021. Patients were stratified into different demographic characteristics and COVID-19 severity scale.

Results:

Of the 598 hospitalized adult COVID19 patients (mean [range] age, 57 [46 to 65] years; 59% male), 300 (50.16%) had severe clinical COVID-19. Comorbidity was high among hospitalized patients (73.5 %), with diabetes mellitus (n=; 46%) and hypertension (n=; 41%) being the most common prevalent. In a multivariate logistic regression model, patient demographics and clinical factors such as age (odds ratio [OR], 1.014 per year; 95% CI, 1.003-1.025), male sex (OR, 1.63; 95% CI, 1.02-2.62), diabetes mellitus (OR, 1.63; 95% CI, 1.06-2.49), obesity (OR, 1.93; 95% CI, 1.26-2.94), oxygen saturation<92% (OR, 4.83; 95% CI, 2.96-7.86), and high neutrophil to lymphocyte ratio (OR, 3.74 per unit; 95% CI, 1.96-7.14) were independently associated with higher COVID-19 severity. Moreover, more than 60% of male patients and middle-aged patients (40-60 years) were associated with the use of COVID-19 medications, including favipiravir and dexamethasone, during their hospital stay. Additionally, the rate of invasive mechanical ventilation was the highest in female patients (61.5%) and in middle-aged patients (46.2%). However, the death rate was slightly higher in males (56%) than in female patients and in elderly patients (52%). In Cox proportional analysis, age associated with increased risk of 60-days mortality (Hazard ratio; HR, 1.05 per year; 95% CI, 1.018-1.098). Additionally, the Riyadh region associated with more COVID-19 cases required invasive respiratory support (57.7%) and Jeddah was associated with more deceased COVID-19 cases (44%).

Conclusions:

The data shows that comorbidity is associated with hospitalization among COVID-19 patients, which indicates the level of severity. Infection during the winter season (November), male gender, elderly, and those with pre-existing diabetes mellitus or obesity were associated with higher COVID-19 clinical severity.

项与 Hevolution Foundation 相关的新闻（医药）

2024-09-18

·PRNewswire

TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging

HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and growth capital firm, today announced a recent equity investment in San Francisco-based Human Longevity, Inc. ( HLI), a global leader since 2013 in advancing precision medicine in the pursuit of healthy aging, often referred to as longevity medicine. The investment will support the company's growth within the U.S. market, as well as its expansion into the Kingdom of Saudi Arabia and Southeast Asia. Founded by Dr. J. Craig Venter, one of the pioneers of the human genome sequencing effort, HLI builds on his vision for a longer, healthier life and the democratization of genomics to revolutionize the way we evade "avoidable disease" and stay healthy longer. The company is recognized as a leader in the rapidly expanding industry of longevity medicine due to its deep expertise in genomics and other fields of precision medicine such as imaging, and its unmatched, longitudinal patient dataset built on decades of research in the field. The company has proprietary tools for the detection of gene-disease associations, including HLI's artificial intelligence health risk and recommendation platform, and provides its clients with pre-symptomatic diagnosis and customized treatments, preempting disease at a very early stage and maximizing health outcomes. In short, HLI is transforming healthcare from a reactive practice to one that is predictive, proactive, and preventative, which not only enhances the quality of lives of individuals but improves the efficiency and efficacy of the entire healthcare system. TVM Capital Healthcare brings extensive global investment experience combined with operating experience in the Middle East and Southeast Asia and a track record of building innovative healthcare companies. Through this investment provided by the Saudi Arabia-focused TVM Healthcare Afiyah Fund LP, which closed earlier this year and is the largest growth capital fund of its kind in the region, the firm will support HLI in its expansion, initially with a special focus on market entry in the Kingdom. The country's Vision 2030 and Health Sector Transformation Program call for an evolution of "sick care" to true "health care," focusing on the most critical fields of oncology, neurology, metabolic syndrome, and diabetes, as well as cardiovascular and autoimmune disease. Saudi Arabia is highly receptive to healthcare business models such as HLI and has been increasingly active in longevity science with several government-backed initiatives, including the Saudi Human Genome Program and the Hevolution Foundation, a Riyadh-headquartered global non-profit organisation, investing in scientific projects and life science companies in the longevity field. Dr. J. Craig Venter, Co-Founder and Chief Scientific Advisor of Human Longevity, Inc., commented: "Human Longevity, Inc. is a health firm where the goal is to stay ahead of aging and illness. We believe this platform will save millions of lives and significantly reduce healthcare costs in the future. TVM Capital Healthcare's investment enables us to strengthen our position globally as the most data-backed longevity practice, as well as establishes our foothold in markets, like Saudi Arabia and SEA, that see the potential of our approach in preventive medicine and the huge impact it will have on changing the cost of medicine." Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare, remarked: "With our investment in HLI, we contribute to the transition towards the 'healthcare of the future' which is all about precision medicine, personalized care, and disease prevention, in short: true 'health care.' The potential long-term impact of longevity medicine in society is immense. We are excited to be part of the journey through this new investment which supports the growth of the company in the U.S., but also introduces HLI into the Kingdom of Saudi Arabia and Southeast Asia." Dr. Ghida Harfouche, Partner at TVM Capital Healthcare, added: "HLI's cutting-edge science has enabled precision medicine for disease prevention and highly personalized interventions for their clients. We are pleased we can support the company in its global growth, and work with them on democratization of healthy longevity and preventative care." TVM Capital Healthcare is recognized as the first international Healthcare fund manager investing in and operating healthcare companies in the Kingdom of Saudi Arabia. The firm is also active across the wider Middle East and Southeast Asia. In addition to backing healthcare growth companies in the U.S. and Europe to support their expansion plans into these regions, TVM Capital Healthcare also invests in leading local companies. With this two-pronged, highly catalytic strategy, TVM Capital Healthcare improves quality and affordable access to world-leading products, technologies, and services across its target markets. ENDS About TVM Capital Healthcare TVM Capital Healthcare is a global healthcare private equity firm specializing in emerging markets. Based in Dubai and Singapore, with offices in Riyadh and Ho Chi Minh City, the firm invests expansion and growth capital in healthcare companies to improve local access to quality and affordable care, as well as local sources of medical products in the pharma, medical device, and diagnostics sectors. Investment and operating partners, as well as a strong group of regional and international senior advisors, have long-standing track records in healthcare investing and deep operating experience in the Middle East and Southeast Asia. Medical quality is safeguarded by collaborations with leading international medical technology and clinical partners such as Mass General Hospital as well as international accreditation agencies such as Joint Commission International (JCI). TVM Capital Healthcare's investment and operating approach combines strong commercial value creation and financial returns with responsible and sustainable investment in alignment with the United Nations Sustainable Development Goals. Our proven strategy in the critical sector of healthcare also includes climate adaptation and resilience. Contact: Holly Radel [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-08-26

·医药观澜

10家创新药公司完成新一轮融资，1家来自中国

▎药明康德内容团队报道根据即刻药数数据库，上周（8月19日~8月25日）全球生物制药领域至少10家致力于创新药研发的公司宣布完成新一轮融资，其中包括1家中国公司。这些获得融资的新锐主要致力于开发小分子药物、RNA疗法、线粒体疗法、癌症免疫疗法等，涉及肾病、肥胖和代谢，心血管以及癌症等治疗领域。 Borealis Biosciences 轮次：A轮金额：1.5亿美元 8月22日，Borealis Biosciences宣布走出隐匿模式并获得创始投资者Versant Ventures和诺华（Novartis）合计1.5亿美元的A轮融资。该公司也与诺华达成战略研究合作，共同开发用于治疗肾脏疾病的RNA疗法。 Borealis旨在通过开发RNA疗法促进科学和转化上的突破，以满足肾病患者的主要未满足需求。该公司的目标包括更好地了解患者分层、遗传学定义的治疗靶标，并致力将治疗有效载荷递送到特定肾细胞类型，以及推进RNA化学的进展。此次诺华参与了Borealis的A轮融资，并承诺提供高达1亿美元的前期和短期研究资金。作为协议的一部分，诺华将有权从Borealis收购两个未来的潜在开发项目，Borealis则有资格在达到临床和监管等里程碑后获得总额达7.5亿美元款项。 Ambrosia Biosciences 轮次：A轮金额：1600万美元 8月21日，Ambrosia Biosciences宣布成功完成A轮融资。本次融资总额为1600万美元，由BVF Partners和Boulder Ventures领投。Ambrosia将利用这笔融资扩大其药物发现项目和实验室运营。 Ambrosia Biosciences专注于发现和开发针对GLP-1受体及其他B类G蛋白偶联受体的全新口服小分子疗法。该公司的研发团队来自原Array BioPharma的药物化学团队。在Array BioPharma被辉瑞收购后，这一团队再度启程，在Ambrosia公司将利用在小分子药物发现方面的专长，开发治疗肥胖症和代谢疾病的药物。 Retension Pharmaceuticals 轮次：A轮金额：1040万美元 8月21日，Retension Pharmaceuticals宣布完成A轮1040万美元融资。Retension是一家临床阶段生物医药公司，专注于开发针对高血压和心血管疾病的创新疗法。该公司的主要候选药物RTN-001是在赛诺菲的全球独家许可下开发，为一款第二代PDE5抑制剂。与早期用于勃起功能障碍的PDE5抑制剂不同，该产品被设计优先分布于心血管组织，从而有望克服第一代PDE5抑制剂在高血压领域的局限性。在此前包括265多名受试者的多项临床试验中，该药耐受性良好，显示出对难治性高血压患者的疗效。根据新闻稿，本轮融资将用于启动RTN-001的一项2期临床研究，针对服用两种或两种以上抗高血压药物仍不受控制的高血压患者。 Pharmazz 轮次：战略投资金额：1500万美元 8月21日，Pharmazz公司宣布和Sun Pharma签署一项协议，Sun Pharma将向Pharmazz投资约1500万美元，支持其完成sovateltide治疗急性脑缺血患者的关键3期研究。同时双方将扩大此前签署的许可协议，Sun Pharma将拥有sovateltide在印度以及其他新兴国家的商业化权利。Sovateltide是一种高选择性内皮素B受体激动剂，可增加血流量，显示抗凋亡活性，保护神经线粒体，促进神经血管重塑。 Pharmazz公司专注于发现、收购、开发和商业化针对重症监护医学的治疗方法，产品类型包括肽和其他小分子药物。该公司正在开发三种针对多种重症监护适应症的新型药品，主要产品centhaquine用于治疗低血容量性休克，第二种化合物Sovateltide用于治疗脑缺血性中风、阿尔茨海默病和其他神经退行性疾病。第三种化合物正在开发中，用于治疗糖尿病酮症酸中毒和消除阿片类药物耐受。 Pathalys Pharma 轮次：B轮金额：1.05亿美元 8月20日，专注于肾病疗法研发的Pathalys Pharma宣布完成1.05亿美元的B轮融资，用于完成两项正在进行的临床试验，向美国FDA申报NDA以及加快批准前的商业化准备。该轮超额融资由TCGX牵头，其他投资者也加入其中，包括JP Morgan Life Sciences Private Capital、Samsara BioCapital、Marshall Wace、KB Investment、JPS Growth Investment Limited Partnership，以及得到了创始投资方Catalys Pacific和DaVita Venture Group的支持。 Pathalys专注的重点领域之一是改进继发性甲状旁腺功能亢进症（SHPT）的治疗。该公司在研疗法upacicalcet是一种新型拟钙剂（calcimimetic）。拟钙剂是一种通过激活钙敏感受体来模仿钙在组织上作用的药物，常用于治疗继发性SHPT。Upacicalcet可在透析结束时通过预填充注射器进行静脉注射。研究表明，它能有效降低甲状旁腺激素水平，并且可能为患者提供更好的耐受性。目前在接受透析的终末期肾病患者中进行的关键性3期临床试验项目已经完成首批患者入组。 GondolaBio 轮次：未知轮金额：3亿美元日前，BridgeBio Pharma公司披露，在投资者的支持下成立了一家名为GondolaBio的新公司，并将针对红细胞生成性原卟啉症、α-1抗胰蛋白酶缺乏症和结节性硬化症的早期临床和临床前项目转移到GondolaBio继续开发。此次GondolaBio的投资者包括Viking Global Investors LP、Patient Square Capital、红杉资本（Sequoia Capital）、Frazier Life Sciences、Cormorant Asset Management、Aisling Capital等机构。这些投资者承诺提供3亿美元的分期融资。同源康医药轮次：IPO 金额：5.06亿港元 8月20日，同源康医药正式在港交所上市，募资约5.06亿港元，约70%将用于核心产品的研究、开发及商业化，约20%将用于其他候选产品研发，约3%将用于潜在战略收购或合作机会。同源康医药致力于开发差异化癌症靶向疗法，以满足亟待满足的医疗需求，尤其是肺癌领域。该公司已建立由11款候选药物组成的管线，包括处于3期关键临床阶段的核心产品TY-9591（第三代EGFR-TKI）、其他6款临床阶段产品，以及4款临床前或早期开发阶段产品。 Vandria SA 轮次：A轮融资金额：3070万美元 8月21日，开发线粒体疗法的Vandria SA宣布完成A轮融资的第二次融资，使其总融资金额达到3070万美元（2830万瑞士法郎）。此次Hevolution Foundation和Dolby Family Ventures加入成为投资方，原创始风险投资公司为ND Capital。 Vandria正在开发一种新靶点小分子诱导剂，可诱导线粒体吞噬（选择性去除和替换受损线粒体）和抗炎作用，有望治疗与年龄相关的慢性疾病。其主要候选者VNA-318在临床前研究中被证明可显著改善记忆和学习。VNA-318在阿尔茨海默病和帕金森病模型中具有强疾病调节作用。而且毒性研究表明其具有广泛的安全窗口。除了VNA-318，Vandria还拥有其他促有丝分裂的小分子管线，以解决肌肉、肺和肝脏疾病中未满足的医疗需求。 PhotonPharma 轮次：种子轮金额：250万美元 8月21日，PhotonPharma宣布完成250万美元的种子轮融资。这笔资金将支持Innocell™的1期临床试验，这是一种治疗晚期癌症的新疗法。该公司成立于2018年，致力于开创新型药物输送系统和靶向治疗，旨在改善癌症治疗。2024年2月，PhotonPharma获得美国FDA的批准开始进行Innocell™的临床开发。临床1期试验预计将于2024年第四季度招募首位患者。 Talus Bioscience 轮次：种子+轮金额：1120万美元 8月20日，Talus Bioscience宣布获得1120万美元的种子+轮融资，由Two Bear Capital领投，WRF Capital、NFX、YC Continuity Fund、Funders Club VC和BoxOne Ventures参投。融资资金将用于推进其在研治疗项目，包括短距离驱动癌症和一种与前列腺有关的非药物转录因子等。 Talus Bio创立于2020年，专注于转录因子调节相关疾病的治疗研发。转录因子通过与DNA结合来协调基因开关进而调节蛋白表达。当它们出现问题时，通常会导致癌症和其他疾病过程。该公司专有发现平台MARMOT（转录因子正常调节的多重检测）集成了人工智能、下一代蛋白质组学、合成化学和计算生物学来设计和研究药物、蛋白质和基因组学。希望在投资市场的助力下，更多前沿技术和创新疗法可以早日造福病患。参考资料： [1]各公司官网和公开资料本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

并购临床2期免疫疗法信使RNA寡核苷酸

2024-04-22

·BioSpace

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Series A financing to advance clinical development of lead candidate RLS-1496 into Phase 1 studies this year in chronic atopic dermatitis and chronic psoriasis. SUNNYVALE, Calif.--(BUSINESS WIRE)-- Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors. This press release features multimedia. View the full release here: Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI The funding will be used to advance the company’s lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, which will be entering Phase 1 studies. Rubedo is also developing additional therapies that selectively target senescent cells in pulmonary diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF), with a program recipient of a substantial CIRM grant last year. “We’re delighted to attract this top-tier syndicate co-led by Khosla Ventures and Ahren Innovation Capital. This significant influx of financing will allow us to advance our first clinical candidate into human studies,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences. “As people live longer, improving quality of life is paramount,” said Alex Morgan, Partner, Khosla Ventures. “Rubedo is targeting senescent, or aging, cells that drive age-related diseases. This first trial can bring us another step closer to achieving better healthspan.” “Our mission is to invest in transformational companies that will change the world for the better, serving vast markets,” said Alice Newcombe Ellis, Founding & General Partner, Ahren Innovation Capital. “We believe that Rubedo’s transformative approach to targeting senescent cells is an impressive step towards the development of chronic age-related therapies, which will advance biotech from treatment to prevention or disease reversal.” “The significant experience and capital that our investors bring to Rubedo will help the company rapidly advance our programs,” said Ali Siam, Chief Business Officer, Rubedo Life Sciences. “We look forward to working with these leaders, whose vast experience in clinical development will be invaluable as we enter the next phase of growth at Rubedo.” Rubedo’s Alembic™ drug discovery platform enables the identification of specific druggable targets for development into therapeutics that selectively target pathologic cells, such as various types of senescent cells, that drive the process of biological aging. Senescence is the process by which a cell ages and permanently stops dividing but does not die. Any cell can potentially become senescent. Over time, large numbers of senescent cells can build up in tissues throughout the body and release pathologic factors. When they reach a critical mass, they cause chronic inflammation and damage leading to fibrosis and tissue degeneration which drive many age-related diseases. About Rubedo Life Sciences Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target various types of senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit . View source version on businesswire.com: Contacts Media Kimberly Ha KKH Advisors 917-291-5744 kimberly.ha@kkhadvisors.com Source: Rubedo Life Sciences Smart Multimedia Gallery Photo Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI Logo View this news release and multimedia online at:

临床1期细胞疗法

100 项与 Hevolution Foundation 相关的药物交易

登录后查看更多信息

100 项与 Hevolution Foundation 相关的转化医学

登录后查看更多信息